Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Metabolic syndrome in haemodialysis patients: prevalence, determinants and association to cardiovascular outcomes

Fig. 3

Distribution of MACE subtypes according to the presence or absence of metabolic syndrome. MetS: Metabolic syndrome. MACE: major adverse cardiovascular events. CHD: coronary heart disease. PAD III-IV: peripheral arterial disease, stage III or IV according to the classification of Leriche and Fontaine. HF: Heart failure. Significant difference (P < 0.05) between MetS+ and MetS- for CHD, PAD III-IV and HF; not significant for Stroke

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us